Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VenCM for Relapsed-Refractory and Induction-Ineligible AML
NCT06537843Phase 2Recruiting
- Sponsor
- Hospital Municipal São José
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in acute myeloid leukemia (AML), sponsored by Hospital Municipal São José. Started Dec 2023; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06537843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537843.